Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Dihydroboldenone (DHB), also known as 1-Testosterone, δ¹-DHT, or 1-androstenedione in some contexts, is a synthetic anabolic-androgenic steroid that exists in non-medical markets exclusively as a research chemical or underground-laboratory product. Despite the name "dihydroboldenone" implying it is a metabolite of boldenone (Equipoise), DHB is more accurately understood as a separate compound that is structurally the 5α-reduced form of boldenone, or equivalently, dihydrotestosterone with an additional double bond between C1 and C2.
The compound has no human therapeutic history, no clinical trial data, and no FDA approval. It was originally encountered as a metabolite of certain steroid prohormones sold over-the-counter in the United States before the 2004 Anabolic Steroid Control Act expanded the controlled substance schedule to include prohormones. Following that regulatory change, DHB transitioned to unregulated production for non-medical use, where it has developed a niche reputation among more experienced users.
Once cleaved from the ester, the dihydroboldenone molecule has a short circulating half-life of several hours. The ester is the rate-limiting step.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Cypionate | ~8–10 days |
| Propionate | ~2–3 days |
| Enanthate | ~7–10 days (less common) |
What it does
Main effects
- High androgen-receptor binding affinity: comparable to or exceeding DHT; published anabolic-to-androgenic ratio of approximately 200:100 (twice as anabolic as testosterone with similar androgenic activity per the older rodent bioassay convention)
- No aromatization to estrogen: 5α-reduced structure prevents conversion; does not produce water retention, gynecomastia, or other estrogen-mediated effects from itself
- No conversion to a different metabolite via 5α-reductase: already 5α-reduced; uniform AR activity across all androgen-responsive tissues
- Lean, sustained muscle accumulation: reputation for "hard, dense" muscle appearance over extended cycles rather than rapid water-weight bulk
- Distinct profile from testosterone, nandrolone, and boldenone: the basis of its niche reputation among experienced users seeking "something different"
What to watch for
Common side effects
- Severe injection-site pain ("DHB pip"): distinctive and consistently reported; substantially more pronounced than most other injectable AAS; often the reason users discontinue
- HPG axis suppression: expected to be substantial given the high direct AR potency; not formally characterized in humans
- HDL reduction and LDL elevation: expected based on non-aromatizing AAS pharmacology; lack of aromatization removes some cardioprotective effect that occurs with testosterone
- Erythrocytosis: AAS-class effect; not formally characterized for DHB
- Severe acne and androgenic skin effects: the high direct AR potency drives this even without 5α-reduction
- Accelerated scalp hair loss in genetically predisposed users: 5α-reductase inhibitors (finasteride, dutasteride) do not protect because DHB does not require 5α-reduction
- Prostatic effects: expected to equal or exceed DHT itself; 5α-reductase inhibitors do not modulate
- Virtually no clinical evidence base: no human PK studies, no clinical trials, no formal safety characterization; dose-response and side-effect rates are unknown
- Underground-only supply with no quality reference standard: particularly difficult to verify product identity; counterfeiting risk is high
Key facts
Key facts worth knowing
- DHB is essentially boldenone without the aromatization-permitting structure, OR equivalently, DHT with the addition of one double bond. Both framings are pharmacologically accurate.
- DHB cannot aromatize to estrogen: the 5α-reduced structure prevents conversion. This is the basis of its reputation as a "non-estrogenic" lean-mass compound.
- DHB cannot be 5α-reduced to a more potent or different metabolite: it is already a 5α-reduced compound. As with other 5α-reduced AAS, this means finasteride and dutasteride do not protect against dihydroboldenone-mediated hair loss in genetically predisposed individuals.
- The compound has a published anabolic-to-androgenic ratio of approximately 200:100 (twice as anabolic as testosterone on a milligram basis with similar androgenic activity), though this ratio derives from animal assays of disputed translational accuracy.
- DHB is notorious for severe injection-site pain (often called "DHB pip" in non-medical communities), significantly more pronounced than with most other injectable AAS. This is one of the most consistently reported subjective features of the compound.
- No human clinical trials of any kind exist. All available information on DHB's effects in humans derives from anecdotal reports, case observation, and inference from related steroid pharmacology.
Legal status
Legal status
Schedule III controlled substance in the United States (DEA). No FDA approval for any indication. WADA-prohibited at all times in competitive sport.